Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track designations in B-NHL -- --